ArticleG3 (Bethesda, Md.)2025
Barcode sequencing: a robust, platform-agnostic method for massively parallel cell-based screens.
Article in G3 (Bethesda, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A time-resolved high-throughput screening of fission yeast deletion mutants for oxidative stress resistance.Microbial cell (Graz, Austria) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Barcode sequencing (Bar-seq) is a high-throughput method originally developed for systematically identifying gene-drug interactions and genetic dependencies in yeast using pooled deletion-mutant libraries. This approach enables high-resolution profiling of large mutant libraries over time, across diverse experimental conditions, providing relative fitness values for each individual within the population. As the technology for enumerating barcodes has evolved, we have continued to incorporate improvements to the method. Here, we present an optimized Bar-seq workflow adaptable to multiple sequencing platforms, including instruments from Illumina, MGI, Element, and Oxford Nanopore. We highlight the advantages and limitations of each approach to aid in experimental design decisions. We introduce refinements in barcode amplification, sequencing strategies, and data analysis to enhance accuracy and scalability while making adoption as straightforward as possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.